HeartSciences Inc.
HSCSHealthcareNASDAQMedical Devices · Last scanned Sep 9, 2026
Scan Results
Daily timeframeHeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. Valued at $18.4M, HSCS is a micro-cap name in its sector. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic ECG management platform.
Market Cap
$18.4M
Beta
1.86
P/E (TTM)
—
P/E (Fwd)
-2.19
EPS (TTM)
$-3.50
EPS (Fwd)
$-1.86
ROE
-4239.9%
ROA
-110.9%
Cash
$1.7M
Total Debt
$3.9M
Free CF
-$2.9M
52W Change
12.7%
Annual Financials
Cash vs Debt
Where HSCS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, HSCS finished 25.42% above its 150-day moving average ($2.40) and 19.44% above its 200-day moving average ($2.52). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HSCS overbought or oversold?
At the September 3, 2026 close, HSCS's RSI(14) was 77.3, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
HeartSciences Inc. carries $3.9M in total debt against $1.7M in cash reserves — debt is roughly 2.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$2.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -4239.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $5K (2023) to $4K (2026), a 16% decline worth watching.
With a beta above 1.5, HSCS tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence HeartSciences Inc.'s trajectory.